A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel

Recent approaches for reducing hemolytic activity of chemotherapeutic agents

“…2) [15]. Jing X et al [56] in 2014 also reported the reduced hemolytic activity of paclitaxel exploiting relevant strategy.…”

“…Hemolysis evaluation of a novel polyethylene glycol mediated intravenous injectable lipid nanoemulsion of paclitaxel demonstrated that lipid nanoemulsion could significantly reduce extraction of RES organs and improve intravenous injection safety including irritation, hemolysis and acute toxicity. In a recent study, on comparing the results of hemolysis with Taxol®, extremely low hemolysis of two-vial formulation of paclitaxel loaded lipid nanoemulsion was found, indicating that two-vial formulation of paclitaxel loaded lipid nanoemulsion could effectively protect hemolysis [28]. Recently, Mayson and team have reported the work based on the microemulsion loaded with Gemcitabine, which is a deoxycytidine analogue, used for cancer therapy.…”

“…A decrease from 100% to 5% was observed in hemolytic activity of sodium oleate with increase of emulsifier concentration from 0 to 5% (w/w) Inclusion of lytic agent into the core of emulsifier at the interface. As a result the direct contact of the lytic agent with the erythrocytic membrane was decreased [10] Paclitaxel Anticancer Lipid nanoemulsion of PEG400 conjugated paclitaxel -Paclitaxel quickly released from nonoemulsion thus preventing uptake by macrophages [28] Paclitaxel Anticancer Two Cremophor-free microemulsions, lecithin:butanol:myvacetoil:water (LBMW) and capmul:myvacet oil:water (CMW)…”

Modification and stabilizing effects of PEG on resveratrol-loaded solid lipid nanoparticles

“…The problems associated with SLNs can be overcome through the use of modifiers such as polymers, carbohydrates, and surfactants [13][14][15]. Polyethylene glycol (PEG2000) has been commonly used as a surface modifier for SLNs to improve the hydrophilicity of the nanoparticle surface, thus extending its circulation time in vivo and decreasing the probability of aggregation and merging [16,17]. However, there are rare reports on the stabilizing effects of doping the lipid matrix with PEG2000 at relatively low concentrations.…”

Development of a validated LC–APCI-MS/MS method to study the plasma and tumor distribution of CHO-PTX intravenous lipid emulsion

“…Over the past decades, paclitaxel has been formulated into different lipid nanosystems such as oil/water emulsions, liposomes, solid lipid nanoparticles, polymeric micelles and nanocapsules [24][25][26][27][28][29][30][31][32][33][34]. These formulations have shown improvements over paclitaxel formulated in Cremophor EL both in vitro and in vivo; however, in most cases the solubilization capacity of paclitaxel in these formulations was limited, and the drug was released rapidly (so-called "burst release") from the formulation [35][36][37].…”